Patients know about pharmacare: let’s listen to them on Bill C-64

Patient groups’ involvement should be built into the program, not just a one-time pre-consultation.

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.